Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02617966 · ClinicalTrials.gov registry record

Rod and Cone Mediated Function in Retinal Disease

A clinical trial of Retinitis Pigmentosa and Retinal Degeneration, sponsored by National Eye Institute (NEI).

Recruiting
Registry status
500
Enrollment target
1
Study location

NCT02617966: Recruiting study of Retinitis Pigmentosa and Retinal Degeneration, sponsored by National Eye Institute (NEI).

NCT02617966 is a study of Retinitis Pigmentosa and Retinal Degeneration that is actively recruiting participants, run by National Eye Institute (NEI). The registered enrollment target is 500 participants, above the 248-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (102% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02617966, a study of Retinitis Pigmentosa and Retinal Degeneration, is actively recruiting participants, sponsored by National Eye Institute (NEI).

RECRUITING
Registry status
500 participants
Enrollment target
1
Study location

Study Summary

Background: Retinal diseases cause the loss of rod and cone photoreceptors. Symptoms include vision loss and night blindness. Researchers want to learn about rod and cone function in healthy people and people with retinal disease. They want to know if how well a person sees in the dark can test the severity of retinal disease. Objectives: To find out if how well a person sees in the dark can test the severity of retinal disease. To find out if this can help detect retinal disease and track its changes. Eligibility: People ages 5 and older with: Retinal disease OR 20/20 vision or better with or without correction in at least one eye Design: Participants will be screened with medical and eye history and eye exam. Those with retinal disease will also have: Eye imaging: Drops dilate the eye and pictures are taken of it. Visual field testing: Participants look into a bowl and press a button when they see light. Electroretinogram (ERG): An electrode is taped to the forehead. Participants sit in the dark with their eyes patched for 30 minutes. Then they get numbing drops and contact lenses. Participants watch lights while retina signals are recorded. Visit 1 will be 3-8 hours. Participants will have up to 6 more visits over 6-12 months. Visits include: Eye exam and imaging Time course of dark adaptation: Participants view a background light for 5 minutes then push a button when they see colored light. Dark adapted sensitivity: Participants sit in the dark for 45 minutes. They push a button when they see colored light. For participants with retinal disease, ERG and visual field testing

Primary Outcome

The primary outcomes for this study are to establish normal ranges for the kinetics of dark adaptation and dark-adapted retinal sensitivity for the fundus guided and non-guided perimeters and for RF hyperacuity on the Display++.

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2016-03-24
Est. Completion 2029-12-30
National Eye Institute (NEI)

221 total trials

What NCT02617966 shows while recruiting

NCT02617966 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 248-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (102% higher).

The record links to 3 conditions, with Retinitis Pigmentosa appearing as the primary indexed condition, and to 0 interventions.

NCT02617966 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT02617966 about?

NCT02617966 is a clinical study titled "Rod and Cone Mediated Function in Retinal Disease". Background: Retinal diseases cause the loss of rod and cone photoreceptors. Symptoms include vision loss and night blindness. Researchers want to learn about rod and cone function in healthy people and people with retinal disease. They want to know if how well a person sees in the dark can test the...

What is the current status of trial NCT02617966?

This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2016-03-24. Estimated completion is 2029-12-30.

What conditions does trial NCT02617966 study?

This clinical trial studies the following conditions: Retinitis Pigmentosa, Retinal Degeneration, Stargardt's Disease.

Who is sponsoring clinical trial NCT02617966?

This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02617966 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Retinitis Pigmentosa

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02617966's enrollment target sits among peer trials

500 5th of 37 higher than 32 of 37 other Retinitis Pigmentosa trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Retinitis Pigmentosa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001230 · 500 participants

    Host Response to Infection and Treatment in Filarial Diseases

  • NCT00001529 · 500 participants

    Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

  • NCT00697411 · 500 participants

    Study of Selected X-Linked Disorders: Aicardi Syndrome

  • NCT00903110 · 500 participants

    Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02617966, the US trial registry maintained by the National Library of Medicine. NCT02617966 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.